Monitor for the full publication of Dr. Calabrese's results later this year, as well as upcoming quarterly earnings (expected 2026 outlook range $200M-$205M revenue per prior 20-F) for any changes in CYTOGAM sales trajectory. No immediate trading catalyst from this clinical data highlight alone.
Drug in focus
KMDA drug pipeline →CYTOGAM
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Next catalyst
- None dated
What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 13 $7.17entry
- T+1 · 4mo ago +1.39%α +1.04% · $7.27
- T+5 · 4mo ago −1.67%α −0.89% · $7.05
- T+20 · 3mo ago −0.42%α −3.60% · $7.14
- T+60 · 6w ago +13.11%α +9.12% · $8.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada announced positive results from an investigator-initiated study of CYTOGAM presented at the 2026 ISHLT annual meeting. The data suggest CYTOGAM use in CMV high-risk lung transplant recipients is associated with improved clinical outcomes and potential immune modulation benefits. While supportive of the product's profile, this is a press release highlighting existing clinical data, not a catalyst with quantifiable revenue impact, and represents routine scientific communication.
Key Facts
- Results from three posters on CYTOGAM (CMVIG) presented at the 2026 ISHLT annual meeting in Toronto
- Retrospective analysis showed CMV high-risk lung transplant recipients not receiving CMVIG had worse clinical outcomes vs those who received it
- Non-clinical in-vivo model suggested CMVIG blunted lung injury and improved mortality
- CYTOGAM is the sole FDA-approved immunoglobulin product for CMV prophylaxis in kidney, lung, liver, pancreas and heart transplantation
- CEO Amir London stated the data support increased product utilization for CYTOGAM
- Full results to be published later this year
Financial Impact
No financial figures or revenue guidance provided in this filing. No material dollar amount cited.
Risk Factors
- Study is investigator-initiated, not a Kamada-sponsored registrational trial, limited direct revenue impact
- Forward-looking statements about increased CYTOGAM utilization remain aspirational without commercial execution proof
- Geopolitical risks from Middle East conflicts and tariffs could affect broader operations as disclosed in the filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-077360 |
| Document: ea0297771-6k_kamada.htm | 0001213900-26-077360 |
| Document: 0001213900-26-077360-index-headers.html | 0001213900-26-077360 |
| Document: 0001213900-26-077360-index.html | 0001213900-26-077360 |
| Document: 0001213900-26-077360.txt | 0001213900-26-077360 |
Track record
25 reports on KMDA
8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers